The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Abstract
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationDE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citationDrug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Self-citationConsensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Self-citationLeucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationAntipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Self-citationThe Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Self-citationWeiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.886 · Cited by 621
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
Neuroleptic Malignant Syndrome
Strawn, J. R., Keck, P. E., & Caroff, S. N. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.870 · Cited by 579
Alper, K., Schwartz, K. A., Kolts, R. L., & Khan, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.023 · Cited by 522
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., MacMillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Kane, J. M., Eerdekens, M., Lindenmayer, J.-P., Keith, S. J., Lesem, M., & Karcher, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1125 · Cited by 489
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01516.x · Cited by 435
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 435
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419
Overview: maintenance therapy in psychiatry: I. Schizophrenia
(1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.12.1237 · Cited by 410
(2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0219 · Cited by 383
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Self-citationTardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282f53132 · Cited by 367
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationLieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Self-citationFalkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Self-citationRosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Kane, J. M. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.1.133 · Cited by 323
Devinsky, O., Honigfeld, G., & Patin, J. (1991) · Neurology · doi:10.1212/wnl.41.3.369 · Cited by 322
Review and management of clozapine side effects.
Miller, D. D. (2000) · PubMed · Cited by 315
Kasper, S., Lerman, M. N., McQuade, R. D., Saha, A., Carson, W. H., Ali, M., Archibald, D., Ingenito, G., Marcus, R., & Pigott, T. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
Self-citationThe Effects of Clozapine on Tardive Dyskinesia
Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.503 · Cited by 302
Self-citationSchooler, N. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830170079011 · Cited by 298
Depot Antipsychotic Drugs: Place in Therapy
Davis, J. M., Metalon, L., Watanabe, M. D., & Blake, L. (1994) · Drugs · doi:10.2165/00003495-199447050-00004 · Cited by 295
The Effects of Novel Antipsychotics on Glucose and Lipid Levels
Wirshing, D. A., Jennifer A., J. A., Meng, L. R., Ballon, J. S., Marder, S. R., & Wirshing, W. C. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1002 · Cited by 294
Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S. E., McEvoy, J. P., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.428 · Cited by 291
Self-citationMaintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 290
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mci.0b013e328303e7a6 · Cited by 289
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M. K. P., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 288
Metabolic syndrome and mental illness.
Newcomer, J. W. (2007) · PubMed · Cited by 285
Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2080 · Cited by 281
Self-citationKane, J. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070083010 · Cited by 273
Laursen, T. M., Munk-Olsen, T., Agerbo, E., Gasse, C., & Mortensen, P. B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.61 · Cited by 271
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Self-citationHough, D., Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., & Eerdekens, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.10.026 · Cited by 265
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
on behalf of the Aripiprazole Study Group, Casey, D. E., Carson, W. H., Saha, A. R., Liebeskind, A., Ali, M. W., Jody, D., & Ingenito, G. G. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1344-3 · Cited by 250
De Hert, M., Schreurs, V., Sweers, K., Van Eyck, D., Hanssens, L., Šinko, S., Wampers, M., Scheen, A., Peuskens, J., & van Winkel, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.028 · Cited by 247
Hert, M. A. F. D., van Winkel, R., Eyck, D. V., Hanssens, L. S., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-14 · Cited by 243
Hogarty, G. E. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330021002 · Cited by 239
Wunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234
Does switching to a new antipsychotic improve outcomes?
Rosenheck, R. A., Davis, S., Covell, N., Essock, S., Swartz, M., Stroup, S., McEvoy, J., & Lieberman, J. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.031 · Cited by 232
Self-citationWu, R.-R., Zhao, J.-P., Guo, X.-F., He, Y.-Q., Fang, M.-S., Guo, W.-B., Chen, J.-D., & Li, L.-H. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010079 · Cited by 230
Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases
Trollor, J. N., & Sachdev, P. S. (1999) · Australian and New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.1999.00630.x · Cited by 226
Voruganti, L., Cortese, L., Oyewumi, L., Cernovsky, Z., Zirul, S., & Awad, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00154-1 · Cited by 226
Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290010048009 · Cited by 222
Interventions to reduce weight gain in schizophrenia
Faulkner, G., Cohn, T., & Remington, G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005148.pub2 · Cited by 222
Gurrera, R. J., Caroff, S. N., Cohen, A., Carroll, B. T., DeRoos, F., Francis, A., Frucht, S., Gupta, S., Levenson, J. L., Mahmood, A., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06438 · Cited by 215
Pandina, G. J., Lindenmayer, J.-P., Lull, J., Lim, P., Gopal, S., Herben, V., Kusumakar, V., Yuen, E., & Palumbo, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181dd3103 · Cited by 214
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 214
Shim, J.-C., Shin, J.-G. K., Kelly, D. L., Jung, D.-U., Seo, Y.-S., Liu, K.-H., Shon, J.-H., & Conley, R. R. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06071075 · Cited by 213
Deep Brain Stimulation: Current and Future Clinical Applications
Lyons, M. K. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0045 · Cited by 201
Menza, M., Vreeland, B., Minsky, S., Gara, M., Radler, D. R., & Sakowitz, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0404 · Cited by 201
Clozapine‐related seizures: Experience with 5,629 patients
Pacia, S. V., & Devinsky, O. (1994) · Neurology · doi:10.1212/wnl.44.12.2247 · Cited by 199
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
Chue, P., Eerdekens, M., Augustyns, I., Lachaux, B., Molčan, P., Eriksson, L., Pretorius, H., & David, A. S. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.003 · Cited by 197
Kane, J. M., Detke, H. C., Naber, D., Sethuraman, G., Lin, D. Y., Bergstrom, R. F., & McDonnell, D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.07081221 · Cited by 197
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111609 · Cited by 193
Self-citationThe Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain
Littrell, K. H., Hilligoss, N. M., Kirshner, C. D., Petty, R. G., & Johnson, C. G. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.00237.x · Cited by 190
Systematic review of patient and nurse attitudes to depot antipsychotic medication
Walburn, J., Gray, R., Gournay, K., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.300 · Cited by 187
Detke, H. C., Zhao, F., Garhyan, P., Carlson, J., & McDonnell, D. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32834093d1 · Cited by 185 · cited 1×
“Patients receiving oral olanzapine in a dose of 10 mg/day can be switched to 405 mg/4 weeks, and patients receiving 15 or 20 mg/day can be switched to 300 mg/2 weeks without increasing risk of relapse (Detke et al. 2011).”
BackgroundCosts and Benefits of Two Doses of Fluphenazine
Marder, S. R. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220015002 · Cited by 182
Conventional Antipsychotic Medications for Schizophrenia
Dixon, L. B., Lehman, A. F., & Levine, J. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.4.567 · Cited by 180
Kramer, M., Litman, R., Hough, D., Lane, R., Lim, P., Liu, Y., & Eerdekens, M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990988 · Cited by 176
Effectiveness of Switching Antipsychotic Medications
Essock, S. M., Covell, N. H., Davis, S. M., Stroup, T. S., Rosenheck, R. A., & Lieberman, J. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2090 · Cited by 172
Self-citationNasrallah, H. A., Gopal, S., Gassmann-Mayer, C., Quiroz, J. A., Lim, P., Eerdekens, M., Yuen, E., & Hough, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.79 · Cited by 170
Gopal, S., Hough, D. W., Xu, H., Lull, J. M., Gassmann-Mayer, C., Remmerie, B. M., Eerdekens, M. H., & Brown, D. W. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833948fa · Cited by 170
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Lambert, M., Schimmelmann, B. G., Naber, D., Schacht, A., Karow, A., Wagner, T., & Czekalla, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1104 · Cited by 169
Kishimoto, T., Agarwal, V, Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 169
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Capuano, G. A., Rosenheck, R. A., Keefe, R. S. E., Miller, A. L., Belz, I., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.415 · Cited by 168
Self-citationTreatment of severe tardive dystonia with pallidal deep brain stimulation
Trottenberg, T., Volkmann, J., Deuschl, G., Kühn, A. A., Schneider, G. H., Müller, J., Alesch, F., & Kupsch, A. (2005) · Neurology · doi:10.1212/01.wnl.0000149762.80932.55 · Cited by 166
Second-generation antipsychotics and constipation: A review of the literature
Hert, M. D., Hudyana, H., Dockx, L., Bernagie, C., Sweers, K., Tack, J. F., Leucht, S., & Peuskens, J. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.03.003 · Cited by 163
Pandina, G., Lane, R., Gopal, S., Gassmann-Mayer, C., Hough, D., Remmerie, B., & Simpson, G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.008 · Cited by 162
Clozapine: Efficacy and Safety
Buchanan, R. W. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.4.579 · Cited by 161
Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder
GOFF, D. C., Hill, M. B., & Freudenreich, O. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9096su1cc.04 · Cited by 157
Clozapine in tardive dyskinesia: observations from human and animal model studies.
Tamminga, C. A., Thaker, G. K., Moran, M. J., Kakigi, T., & Gao, X. (1994) · PubMed · Cited by 156
Manu, P., Sarpal, D. K., Muir, O. S., Kane, J. M., & Correll, C. U. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.10.014 · Cited by 152
Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., Tso, S., Pang, E. P. F., Chan, K. T., Wong, Y. C., et al. (2010) · BMJ · doi:10.1136/bmj.c4024 · Cited by 151
The case for long‐acting antipsychotic agents in the post‐CATIE era
Nasrallah, H. A. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00982.x · Cited by 149
Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics
Nielsen, J., Graff, C., Kanters, J. K., Toft, E. S., Taylor, D. M., & Meyer, J. M. (2011) · CNS Drugs · doi:10.2165/11587800-000000000-00000 · Cited by 149
Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study
Weiden, P. J., Mann, J. J., Haas, G. L., Mattson, M., & FRANCES, A. J. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1148 · Cited by 147
Baptista, T., Rangel, N., Fernández, V., Carrizo, E., Fakih, Y. E., Uzcátegui, E., Galeazzi, T., Gutiérrez, M. A. M., Servigna, M., Dávila, A., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.029 · Cited by 144
Olivares, J. M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., & Lam, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.12.002 · Cited by 141
Newcomer, J. W., Campos, J. A. D. O., Marcus, R. N., Breder, C. D., Berman, R., Kerselaers, W., L'Italien, G. J., Nys, M., Carson, W. H., & McQuade, R. D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0702 · Cited by 141
Results of phase 3 of the CATIE schizophrenia trial
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Thomas, S., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.011 · Cited by 141
Self-citationLong-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
Colonna, L., Saleem, P., Dondey-Nouvel, L., & Rein, W. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00002 · Cited by 139
Revicki, D. A., Genduso, L. A., Hamilton, S. H., Ganoczy, D. A., & Beasley, C. M. (1999) · Quality of Life Research · doi:10.1023/a:1008958925848 · Cited by 137
Baandrup, L., Gasse, C., Jensen, V. D., Glenthoj, B. Y., Nordentoft, M., Lublin, H., Fink‐Jensen, A., Lindhardt, A., & Mortensen, P. B. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04818yel · Cited by 137
Self-citationVitamin E for neuroleptic-induced tardive dyskinesia
Soares‐Weiser, K., Maayan, N., & McGrath, J. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000209.pub2 · Cited by 137
Baptista, T., Martínez, J., Lacruz, A., Rangel, N., Beaulieu, S., Serrano, A., Arapé, Y., Martinez, M., Mendoza, S., Teneud, L., et al. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100310 · Cited by 134
Olanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 134
Self-citationGäebel, W., Jänner, M., Frommann, N., Pietźcker, A., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., & Tegeler, J. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00182-7 · Cited by 133
Hogarty, G. E., & Ulrich, R. F. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00013-7 · Cited by 130
Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
Weiden, P. J., Simpson, G. M., Potkin, S. G., & O’Sullivan, R. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0514 · Cited by 130
Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials
Bollini, P., Pampallona, S., Orza, M. J., Adams, M. E., & Chalmers, T. C. (1994) · Psychological Medicine · doi:10.1017/s003329170002729x · Cited by 129
Haro, J. M., Suarez, D. L., Novick, D., Brown, J., Usall, J., & Naber, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.09.005 · Cited by 126
A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
Henderson, D. C., Copeland, P. M., Daley, T. B., Borba, C. P. C., Cather, C., Nguyen, D. D., Louie, P. M., Evins, A. E., Freudenreich, O., Hayden, D. L., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.954 · Cited by 126
Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia
Awad, A. G., & Voruganti, L. N. P. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00004 · Cited by 125
Long-Acting Risperidone: A Review of Its Use in Schizophrenia
Harrison, T. S., & Goa, K. L. (2004) · CNS Drugs · doi:10.2165/00023210-200418020-00005 · Cited by 125
Спивак, Б., Mester, R., Abesgaus, J., et al. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0706 · Cited by 125
Guidelines for Neuroleptic Relapse Prevention in Schizophrenia
(1991) · Springer eBooks · doi:10.1007/978-3-642-86922-8 · Cited by 124
Metformin for olanzapine‐induced weight gain: a systematic review and meta‐analysis
Praharaj, S. K., Jana, A. K., Goyal, N., & Sinha, V. K. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03783.x · Cited by 123
Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone
Weiden, P. J., Daniel, D. G., Simpson, G. M., & Romano, S. J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095347.32154.08 · Cited by 123
Course and Outcome of Schizophrenia
Häfner, H., & der Heiden, W. A. (2003) · Wiley eBooks · doi:10.1002/9780470987353.ch8 · Cited by 121
Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C. C., & McDonnell, D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0512 · Cited by 120 · cited 2×
“No other concomitant oral antipsychotic treatment was permitted (Lauriello et al. 2008).”
BackgroundGäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 119
The Pharmacologic Treatment of Neuroleptic-Induced Akathisia
Fleischhacker, W. W., Roth, S. D., & Kane, J. M. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199002000-00003 · Cited by 119
Detke, H. C., McDonnell, D., Brunner, E., Zhao, F., Sorsaburu, S., Stefaniak, V. J., & Corya, S. A. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-43 · Cited by 118
Managing an effective treatment for neuroleptic malignant syndrome
Reulbach, U., Dütsch, C., Biermann, T., Sperling, W., Thuerauf, N., Kornhuber, J., & Bleich, S. (2007) · Critical Care · doi:10.1186/cc5148 · Cited by 117
Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia
Carpenter, W. T., Buchanan, R. W., Kirkpatrick, B. W., & Breier, A. F. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.299 · Cited by 117
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia
Fleischhacker, W. W., Gopal, S., Lane, R., Gassmann-Mayer, C., Lim, P., Hough, D. W., Remmerie, B. M. M., & Eerdekens, M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001076 · Cited by 117
Hamilton, S. H. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00111-5 · Cited by 117
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia
Hough, D. W., Lindenmayer, J., Gopal, S., Melkote, R., Lim, P., Herben, V. M. M., Yuen, E., & Eerdekens, M. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.05.014 · Cited by 116
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
Beyond signs and symptoms: the case against a mixed anxiety and depression category.
Davis, J. M., Kane, J. M., Marder, S. R., Brauzer, B., Gierl, B., Schooler, N., Casey, D. E., & Hassan, M. (1993) · PubMed · Cited by 115
Semple, D. M., & Smyth, R. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199239467.001.0001 · Cited by 113
Role of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111
Emsley, R. A., Oosthuizen, P., Koen, L., Niehaus, D. J. H., Medori, R., & Rabinowitz, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32830c2042 · Cited by 111
The CATIE and CUtLASS Studies in Schizophrenia: Results and Implications for Clinicians
Naber, D., & Lambert, M. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00002 · Cited by 109
Rubio, G., Martínez, I., Ponce, G., Jiménez‐Arriero, M. Á., Lopez-Munoz, F. J., & Álamo, C. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100808 · Cited by 109
Johnson, D. A. W., Ludlow, J. M., Street, K., & Taylor, R. D. W. (1987) · The British Journal of Psychiatry · doi:10.1192/bjp.151.5.634 · Cited by 108
Weiden, P. J., Schooler, N. R., Weedon, J. C., Elmouchtari, A., Sunakawa-McMillan, A., & Goldfinger, S. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05284yel · Cited by 106
Narula, P. K., Rehan, H. S., Unni, K. E. S., & Gupta, N. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.001 · Cited by 105
Evidence-based pharmacotherapy of schizophrenia
Leucht, S., Heres, S., Kissling, W., & Davis, J. M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001380 · Cited by 105
Citrome, L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02240.x · Cited by 104
Kim, K., Pae, C., Chae, J., Bahk, W., Jun, T.-Y., Kim, D., & Dickson, R. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0506 · Cited by 104
Emsley, R. A., Turner, H. J., Schronen, J., Botha, K., Smit, R., & Oosthuizen, P. P. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0516 · Cited by 104
Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management
Holt, R. I. G., & Peveler, R. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03814.x · Cited by 103
Ko, Y., Joe, S.-H., Jung, I., & Kim, S. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000172994.56028.c3 · Cited by 103
Gopal, S., Vijapurkar, U., Lim, P., Ma, M., Eerdekens, M., & Hough, D. W. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372817 · Cited by 103
Poyurovsky, M., Pashinian, A., Gil‐Ad, I., Maayan, R., Schneidman, M., Fuchs, C., & Weizman, A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1058 · Cited by 103
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., ZHU, Y., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 102
Carrière, P., Bonhomme, D., & Lempérière, T. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00401-6 · Cited by 100
Topiramate Add-On in Treatment-Resistant Schizophrenia
Tiihonen, J., Halonen, P. M., Wahlbeck, K., Repo‐Tiihonen, E., Hyvärinen, S., Eronen, M., Putkonen, H., Takala, P., Mehtonen, O. ‐., Puck, M., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0808 · Cited by 98
Maintenance Treatment of Schizophrenia With Risperidone or Haloperidol: 2-Year Outcomes
Marder, S. R., Glynn, S. M., Wirshing, W. C., Wirshing, D. A., Ross, D., Widmark, C., Mintz, J., Liberman, R. P., & Blair, K. E. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1405 · Cited by 98
McDonnell, D. P., Detke, H. C., Bergstrom, R. F., Kothare, P., Johnson, J., Stickelmeyer, M., Sanchez-Felix, M. V., Sorsaburu, S., & Mitchell, M. I. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-45 · Cited by 96
Li, H., Rui, Q., Ning, X., Xu, H., & Gu, N. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.001 · Cited by 96
Kinon, B., AHL, J. S. B., Liu‐Seifert, H., & Maguire, G. A. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.12.006 · Cited by 95
Treatment of Late-life Schizophrenia With Neuroleptics
Jeste, D. V., Lacro, J. P., Gilbert, P., Kline, J., & Kline, N. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.4.817 · Cited by 94
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial
Cavazzoni, P. A., Tanaka, Y., Roychowdhury, S. M., Breier, A., & Allison, D. B. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00127-x · Cited by 94
Gäebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., JOCKERS-SCHERÜBL, M. C., Kühn, K.-U., Lemke, M., Bechdolf, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1116 · Cited by 93
Self-citationHamilton, S. H., Edgell, E. T., Revicki, D. A., & Breier, A. F. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015050-00001 · Cited by 93
Interventions to Reduce Weight Gain in Schizophrenia
Faulkner, G., Cohn, T. A., & Remington, G. J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm022 · Cited by 93
Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., Lemke, M., Heuser, I., Maier, W., Huff, W., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05459yel · Cited by 92 · cited 1×
“…disease were shown to be inferior to continued treatment as they result in a higher frequency of relapse and hospital admissions in fi rst-episode and multipleepisode schizophrenia patients (Schooler 1993; Schooler et al. 1997; Wunderink et al. 2007; Gaebel et al. 2002, 2011; Takeuchi et al. 2012).”
BackgroundSelf-citationGraham, K. A., Gu, H., Lieberman, J. A., Harp, J. B., & Perkins, D. O. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.9.1744 · Cited by 92 · cited 1×
“In a small doubleblind, placebo-controlled study, amantadine was superior to placebo as an addition to olanzapine with regard to weight loss (Graham et al. 2005).”
BackgroundSelf-citationAfshar, H., Roohafza, H., Mousavi, S. G., Golchin, S., Toghianifar, N., Sadeghi, M., & Talaei, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089816 · Cited by 92
Akathisia and second-generation antipsychotic drugs
Kumar, R., & Sachdev, P. S. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32832a16da · Cited by 92
Praxisleitlinien in Psychiatrie und Psychotherapie
Menke, R., Wobrock, T., Weinmann, S., Janssen, B., Falkai, P., & Gäebel, W. (2006) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747.54.1.3 · Cited by 92
Self-citationGrimaldi‐Bensouda, L., Rouillon, F., Astruc, B., Rossignol, M., Bénichou, J., Falissard, B., Limosin, F., Beaufils, B., Vaïva, G., Verdoux, H., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.10.022 · Cited by 91
Self-citationBai, Y. M., Chen, T. T., Chen, J. Y., Wu, W.-H., Hung, C. H., & Lin, W. K. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0808 · Cited by 91
Weight loss in overweight patients maintained on atypical antipsychotic agents
Centorrino, F., Wurtman, J. J., Duca, K., Fellman, V., Fogarty, K. V., Berry, J. M., Guay, D. M., Romeling, M., KIDWELL, J. E., Cincotta, S. L., et al. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803222 · Cited by 89
Amantadine for weight gain associated with olanzapine treatment
Deberdt, W. G., Winokur, A., Cavazzoni, P. A., Trzaskoma, Q., Carlson, C. D., Bymaster, F. P., Wiener, K., Floris, M., & Breier, A. F. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.03.005 · Cited by 86
Effect of amantadine on weight gain during olanzapine treatment
Floris, M., Lejeune, J., & Deberdt, W. G. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00072-4 · Cited by 86
Keks, N. A., Ingham, M., Khan, A., & Karcher, K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.017020 · Cited by 85
Simpson, G. M., Mahmoud, R. A., Lasser, R. A., Kujawa, M. J., Bossie, C. A., Turkoz, I., Rodriguez, S., & Gharabawi, G. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0804 · Cited by 84
Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?
Cheung, H. K. (1981) · The British Journal of Psychiatry · doi:10.1192/bjp.138.6.490 · Cited by 82
Amantadine in the Treatment of Neuroendocrine Side Effects of Neuroleptics
Correa, N., Opler, L. A., Kay, S. R., & Birmaher, B. B. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198704000-00008 · Cited by 81
Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone
Weiden, P. J., Newcomer, J. W., Loebel, A. D., Yang, R., & Lebovitz, H. E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301482 · Cited by 80
A pilot study of a weight management program with food provision in schizophrenia
JEANBAPTISTE, M., Tek, C., Liskov, E., CHAKUNTA, U., Nicholls, S. J., HASSAN, A., Brownell, K. D., & Wexler, B. E. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.022 · Cited by 80
Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck, R., Dunn, L. A., Peszke, M. A., Cramer, J. A., Xu, W., Thomas, J. V., & Charney, D. S. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.88 · Cited by 79
Antipsychotic long-acting injections: Mind the gap
Patel, M. X., Taylor, M., & David, A. S. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s1 · Cited by 79
Anticholinergic medication for neuroleptic-induced tardive dyskinesia
Soares‐Weiser, K., Mobsy, C., & Holliday, E. (1997) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000204 · Cited by 77
How to read and understand and use systematic reviews and meta‐analyses
Leucht, S., Kissling, W., & Davis, J. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01388.x · Cited by 76
Arman, S., Sadramely, M. R., Nadi, M., & Koleini, N. (2008) · Saudi Medical Journal · doi:10.15537/1658-3175.4426 · Cited by 75
Lindenmayer, J., & Khan, A. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.021 · Cited by 74
Gopal, S., Gassmann-Mayer, C., Palumbo, J., Samtani, M. N., Shiwach, R., & Alphs, L. D. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903482772 · Cited by 74
Benzodiazepines for neuroleptic-induced acute akathisia
Lima, A. R., Soares‐Weiser, K., Bacaltchuk, J., & Barnes, T. R. E. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001950 · Cited by 73
Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Bellinghieri, P. M., Scimeca, G., Cacciola, M., Campolo, D., Settineri, S., & Zoccali, R. A. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372548 · Cited by 73
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity
Joffe, G., Takala, P., Tchoukhine, E., Hakko, H. H., Raidma, M., Putkonen, H., Eronen, M., & Räsänen, P. K. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0503 · Cited by 71
Anticholinergics for neuroleptic-induced acute akathisia
Rathbone, J., & Soares‐Weiser, K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003727.pub3 · Cited by 70
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study
Lee, B.-H., Kim, Y., & Park, S.-H. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.02.001 · Cited by 70
Risperidone Maintenance Treatment in Schizophrenia: A Randomized, Controlled Trial
Wang, C., Xiang, Y., Cai, Z., Weng, Y., Bo, Q., Zhao, J., Liu, T., Wang, G., Weng, S.-M., Zhang, H., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030358 · Cited by 70
Cited by
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Ringen, P. A., Engh, J. A., Birkenaes, A. B., Dieset, I., & Andreassen, O. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00137 · Cited by 339
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
“The World Federation of Societies of Biological Psychiatry (WFSBP) has published a guideline on the long-term treatment of schizophrenia and management of antipsychotic-induced adverse effects (Hasan et al., 2013), which includes the management of weight gain and metabolic changes.”
Background
Metadata
- Authors
- Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2012-12-06
- Volume
- 14
- Issue
- 1
- Pages
- 2-44
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2107201157
- Cited by
- 416
- References
- 302
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.